RB-pathway disruption in breast cancer

Differential association with disease subtypes, disease-specific prognosis and therapeutic response

Adam Ertel, Jeffry L. Dean, Hallgeir Rui, Chengbao Liu, Agnes K. Witkiewicz, Karen E. Knudsen, Erik S. Knudsen

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

In breast cancer, inactivation of the RB tumor suppressor gene is believed to occur via multiple mechanisms to facilitate tumorigenesis. However, the prognostic and predictive value of RB status in disease-specific clinical outcomes has remained uncertain. We investigated RB pathway deregulation in the context of both ER-positive and ER-negative disease using combined microarray datasets encompassing over 900 breast cancer patient samples. Disease-specific characteristics of RB pathway deregulation were investigated in this dataset by evaluating correlation among pathway genes as well as differential expression across patient tumor populations defined by ER status. Survival analysis among these breast cancer samples demonstrates that the RB-loss signature is associated with poor disease outcome within several independent cohorts. Within the ER-negative subpopulation, the RB-loss signature is associated with improved response to chemotherapy and longer relapse-free survival. Additionally, while individual genes in the RB target signature closely reproduce its prognostic value, they also serve to predict and monitor response to therapeutic compounds, such as the cytostatic agent PD-0332991. These results indicate that the RB-loss signature expression is associated with poor outcome in breast cancer, but predicts improved response to chemotherapy based on data in ER-negative populations. While the RB-loss signature, as a whole, demonstrates prognostic and predictive utility, a small subset of markers could be sufficient to stratify patients based on RB function and inform the selection of appropriate therapeutic regimens.

Original languageEnglish (US)
Pages (from-to)4153-4163
Number of pages11
JournalCell Cycle
Volume9
Issue number20
DOIs
StatePublished - Oct 15 2010

Fingerprint

Breast Neoplasms
Drug Therapy
Cytostatic Agents
Therapeutics
Survival Analysis
Tumor Suppressor Genes
Population
Genes
Carcinogenesis
Recurrence
Survival
Neoplasms
Datasets
palbociclib

Keywords

  • Breast cancer
  • Cytostatics
  • Microarray
  • Proliferation
  • RB

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

RB-pathway disruption in breast cancer : Differential association with disease subtypes, disease-specific prognosis and therapeutic response. / Ertel, Adam; Dean, Jeffry L.; Rui, Hallgeir; Liu, Chengbao; Witkiewicz, Agnes K.; Knudsen, Karen E.; Knudsen, Erik S.

In: Cell Cycle, Vol. 9, No. 20, 15.10.2010, p. 4153-4163.

Research output: Contribution to journalArticle

Ertel, Adam ; Dean, Jeffry L. ; Rui, Hallgeir ; Liu, Chengbao ; Witkiewicz, Agnes K. ; Knudsen, Karen E. ; Knudsen, Erik S. / RB-pathway disruption in breast cancer : Differential association with disease subtypes, disease-specific prognosis and therapeutic response. In: Cell Cycle. 2010 ; Vol. 9, No. 20. pp. 4153-4163.
@article{3ed88862350f4c61b27c5b36870a23f8,
title = "RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response",
abstract = "In breast cancer, inactivation of the RB tumor suppressor gene is believed to occur via multiple mechanisms to facilitate tumorigenesis. However, the prognostic and predictive value of RB status in disease-specific clinical outcomes has remained uncertain. We investigated RB pathway deregulation in the context of both ER-positive and ER-negative disease using combined microarray datasets encompassing over 900 breast cancer patient samples. Disease-specific characteristics of RB pathway deregulation were investigated in this dataset by evaluating correlation among pathway genes as well as differential expression across patient tumor populations defined by ER status. Survival analysis among these breast cancer samples demonstrates that the RB-loss signature is associated with poor disease outcome within several independent cohorts. Within the ER-negative subpopulation, the RB-loss signature is associated with improved response to chemotherapy and longer relapse-free survival. Additionally, while individual genes in the RB target signature closely reproduce its prognostic value, they also serve to predict and monitor response to therapeutic compounds, such as the cytostatic agent PD-0332991. These results indicate that the RB-loss signature expression is associated with poor outcome in breast cancer, but predicts improved response to chemotherapy based on data in ER-negative populations. While the RB-loss signature, as a whole, demonstrates prognostic and predictive utility, a small subset of markers could be sufficient to stratify patients based on RB function and inform the selection of appropriate therapeutic regimens.",
keywords = "Breast cancer, Cytostatics, Microarray, Proliferation, RB",
author = "Adam Ertel and Dean, {Jeffry L.} and Hallgeir Rui and Chengbao Liu and Witkiewicz, {Agnes K.} and Knudsen, {Karen E.} and Knudsen, {Erik S.}",
year = "2010",
month = "10",
day = "15",
doi = "10.4161/cc.9.20.13454",
language = "English (US)",
volume = "9",
pages = "4153--4163",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "20",

}

TY - JOUR

T1 - RB-pathway disruption in breast cancer

T2 - Differential association with disease subtypes, disease-specific prognosis and therapeutic response

AU - Ertel, Adam

AU - Dean, Jeffry L.

AU - Rui, Hallgeir

AU - Liu, Chengbao

AU - Witkiewicz, Agnes K.

AU - Knudsen, Karen E.

AU - Knudsen, Erik S.

PY - 2010/10/15

Y1 - 2010/10/15

N2 - In breast cancer, inactivation of the RB tumor suppressor gene is believed to occur via multiple mechanisms to facilitate tumorigenesis. However, the prognostic and predictive value of RB status in disease-specific clinical outcomes has remained uncertain. We investigated RB pathway deregulation in the context of both ER-positive and ER-negative disease using combined microarray datasets encompassing over 900 breast cancer patient samples. Disease-specific characteristics of RB pathway deregulation were investigated in this dataset by evaluating correlation among pathway genes as well as differential expression across patient tumor populations defined by ER status. Survival analysis among these breast cancer samples demonstrates that the RB-loss signature is associated with poor disease outcome within several independent cohorts. Within the ER-negative subpopulation, the RB-loss signature is associated with improved response to chemotherapy and longer relapse-free survival. Additionally, while individual genes in the RB target signature closely reproduce its prognostic value, they also serve to predict and monitor response to therapeutic compounds, such as the cytostatic agent PD-0332991. These results indicate that the RB-loss signature expression is associated with poor outcome in breast cancer, but predicts improved response to chemotherapy based on data in ER-negative populations. While the RB-loss signature, as a whole, demonstrates prognostic and predictive utility, a small subset of markers could be sufficient to stratify patients based on RB function and inform the selection of appropriate therapeutic regimens.

AB - In breast cancer, inactivation of the RB tumor suppressor gene is believed to occur via multiple mechanisms to facilitate tumorigenesis. However, the prognostic and predictive value of RB status in disease-specific clinical outcomes has remained uncertain. We investigated RB pathway deregulation in the context of both ER-positive and ER-negative disease using combined microarray datasets encompassing over 900 breast cancer patient samples. Disease-specific characteristics of RB pathway deregulation were investigated in this dataset by evaluating correlation among pathway genes as well as differential expression across patient tumor populations defined by ER status. Survival analysis among these breast cancer samples demonstrates that the RB-loss signature is associated with poor disease outcome within several independent cohorts. Within the ER-negative subpopulation, the RB-loss signature is associated with improved response to chemotherapy and longer relapse-free survival. Additionally, while individual genes in the RB target signature closely reproduce its prognostic value, they also serve to predict and monitor response to therapeutic compounds, such as the cytostatic agent PD-0332991. These results indicate that the RB-loss signature expression is associated with poor outcome in breast cancer, but predicts improved response to chemotherapy based on data in ER-negative populations. While the RB-loss signature, as a whole, demonstrates prognostic and predictive utility, a small subset of markers could be sufficient to stratify patients based on RB function and inform the selection of appropriate therapeutic regimens.

KW - Breast cancer

KW - Cytostatics

KW - Microarray

KW - Proliferation

KW - RB

UR - http://www.scopus.com/inward/record.url?scp=77958510718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958510718&partnerID=8YFLogxK

U2 - 10.4161/cc.9.20.13454

DO - 10.4161/cc.9.20.13454

M3 - Article

VL - 9

SP - 4153

EP - 4163

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 20

ER -